Tenaya Therapeutics recently reported a reduced net loss of US$19.27 million for the first quarter of 2026 and, in April, ...

As of Monday, May 18, Tenaya Therapeutics, Inc.’s TNYA share price has dipped by 9.02%, which has investors questioning if ...

ASGCT Presentations Include Preclinical Data for TN-401 PKP2 and DWORF Gene Therapy Programs and AAV Capsid Engineering Innovations TN-401 is Tenaya’s gene therapy candidate being developed for the ...

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

(NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, presented ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...

According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 31.1% and a 54.0% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the ...